Key points are not available for this paper at this time.
Design
Review
May inform clinician awareness of pipeline agents; leaves open validation in prospective trials.
This review presents a brief overview of some of the many exciting developments that are taking place in the field of cardiovascular pharmacology. Research continues to progress at a rapid rate, and we can expect many drugs to enter the clinical arena within the next few years. It must be borne in mind, however, that the pharmaceutical industry and hospital budgetary restrictions sometimes limit drug development and occasionally interrupt clinical trials, even before their results have been obtained.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: